If you're in the bull camp on SKUL, then I would wait until after its report and look for long-biased trades if this stock manages to break out above its 50-day moving average of $6.83 a share and then once it takes out more overhead resistance at $6.94 to $7.09 with high volume. Look for volume on that move that registers near or above its three-month average action of 688,837 shares. If that breakout hits, then SKUL will set up to re-test or possibly take out its next major overhead resistance levels at $7.40 to $8 a share. Any high-volume move above $8 will then put its next major overhead resistance levels at $8.75 to $9 into range for shares of SKUL.
I would simply avoid SKUL or look for short-biased trades if after earnings it fails to trigger that breakout, and then drops back below some key near-term support levels at $6.01 to $5.98 a share with high volume. If we get that move, then SKUL will set up to enter new 52-week- and all-time-low territory below $5.98 a share, which is bearish price action. Some possible downside targets off that move are $5 to $4 a share.
Another earnings short-squeeze prospect is biotechnology and drugs player
(SRPT - Get Report)
, which is set to release numbers on Thursday before the market open. Wall Street analysts, on average, expect Sarepta Therapeutics to report revenue of $6.71 million on a loss of 29 cents per share.
Just this morning, Leerink Swann initiated coverage of Sarepta Therapeutics with an outperform rating and a $45 price target on the stock.
The current short interest as a percentage of the float for Sarepta Therapeutics is pretty high at 15.6%. That means that out of the 23.06 million shares in the tradable float, 4.12 million shares are sold short by the bears. The bears have also been increasing their bets from the last reporting period by 7.5%, or by about 287,000 shares. If the bears are caught leaning too hard into a bullish quarter, then shares of SRPT could explode higher post-earnings.